BioCatalystWatch
BMYWorkspace / BMY / OverviewCompany library
BRISTOL MYERS SQUIBB CO logo

BRISTOL MYERS SQUIBB CO

BRISTOL MYERS SQUIBB CO (BMY)

Price
Market cap
Next catalystDec 12-15, 2026iberdomide plus daratumumab and dexamethasone — EXCALIBER-RRMM · Phase 3 dataSEC filing ↗
Cash

Chart & Events

Candle interval

Core Clinical

Cobenfy

M1 muscarinic receptor × M4 muscarinic receptor × Peripheral muscarinic receptors

PreINDP1P2P3FilingApproved
Upcoming / outlook

Cobenfy

M1 muscarinic receptor × M4 muscarinic receptor × Peripheral muscarinic receptors

PreINDP1P2P3FilingApproved
Cobenfy

M1 muscarinic receptor × M4 muscarinic receptor × Peripheral muscarinic receptors

Upcoming / outlook

Cobenfy

M1 muscarinic receptor × M4 muscarinic receptor × Peripheral muscarinic receptors

Upcoming / outlook

Cobenfy

M1 muscarinic receptor × M4 muscarinic receptor × Peripheral muscarinic receptors

Upcoming / outlook

Cobenfy

M1 muscarinic receptor × M4 muscarinic receptor × Peripheral muscarinic receptors

PreINDP1P2P3FilingApproved
Upcoming / outlook

Cobenfy

M1 muscarinic receptor × M4 muscarinic receptor × Peripheral muscarinic receptors

Upcoming / outlook

Cobenfy

M1 muscarinic receptor × M4 muscarinic receptor × Peripheral muscarinic receptors

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Cobenfy

M1 muscarinic receptor × M4 muscarinic receptor × Peripheral muscarinic receptors

PreINDP1P2P3FilingApproved
Upcoming / outlook

Cobenfy

M1 muscarinic receptor × M4 muscarinic receptor × Peripheral muscarinic receptors

PreINDP1P2P3FilingApproved
Upcoming / outlook

pumitamig

pumitamig

PRMT5

PreINDP1P2P3FilingApproved

PRMT5

PreINDP1P2P3FilingApproved
golcadomide

Cereblon (CRBN)

PreINDP1P2P3FilingApproved
Upcoming / outlook

BMS-986365

Androgen receptor (AR)

PreINDP1P2P3FilingApproved
Upcoming / outlook

BMS-986489

Fucosyl-GM1 + PD-1

PreINDP1P2P3FilingApproved

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

golcadomide

Cereblon (CRBN)

PreINDP1P2P3FilingApproved
Upcoming / outlook

Cobenfy

M1 muscarinic receptor × M4 muscarinic receptor × Peripheral muscarinic receptors

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Cobenfy

M1 muscarinic receptor × M4 muscarinic receptor × Peripheral muscarinic receptors

PreINDP1P2P3FilingApproved
Upcoming / outlook

Other pipelines

PD-1

PreINDP1P2P3FilingApproved
Reblozyl (luspatercept-aamt)

TGF-β ligands

PreINDP1P2P3FilingApproved
Reblozyl (luspatercept-aamt)

TGF-β ligands

PreINDP1P2P3FilingApproved

CCR8

PreINDP1P2P3FilingApproved

CCR8

PreINDP1P2P3FilingApproved

CCR8

PreINDP1P2P3FilingApproved

CCR8

PreINDP1P2P3FilingApproved

Partner / License out

iza-bren (BL-B01D1)

EGFR × HER3

PreINDP1P2P3FilingApproved
iza-bren (BL-B01D1)

EGFR × HER3

PreINDP1P2P3FilingApproved

EGFR × HER3

PreINDP1P2P3FilingApproved

EGFR × HER3

PreINDP1P2P3FilingApproved

TYK2

PreINDP1P2P3FilingApproved

IL-2

PreINDP1P2P3FilingApproved

IL-2

PreINDP1P2P3FilingApproved

Approved / commercial

Sotyktu (deucravacitinib)

TYK2

Approved

PreINDP1P2P3FilingApproved
Cobenfy

M1 muscarinic receptor × M4 muscarinic receptor × Peripheral muscarinic receptors

Approved

PreINDP1P2P3FilingApproved
Camzyos (mavacamten)

Cardiac myosin

PreINDP1P2P3FilingApproved

Cereblon (CRBN)

PreINDP1P2P3FilingApproved

KRAS G12C

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

KRAS G12C

Approved

PreINDP1P2P3FilingApproved

ROS1 × NTRK/TRK

Approved

PreINDP1P2P3FilingApproved

ROS1 × NTRK/TRK

Approved

PreINDP1P2P3FilingApproved

History / paused

BCMA × CD3

PreINDP1P2P3FilingApproved

PreINDP1P2P3FilingApproved

PD-1 × LAG-3

PreINDP1P2P3FilingApproved

LAG-3

PreINDP1P2P3FilingApproved

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Operating
Investing
Financing

Reported shares and borrowings

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

BMY PR & News

PR & News

BMY SEC archive